Intellia Therapeutics (NTLA) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Stifel Reiterates Buy Rating on Intellia Therapeutics (NTLA)
November 7, 2024 10:43 AM ESTStifel analyst Dae Gon Ha reiterated a Buy rating and $54.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "NTLA has one of the most expansive and diversified pipelines within the CRISPR/Cas gene editing field, and with 3 Ph.3 studies... More



